Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 11 October 2017, 11:48 HKT/SGT
Share:
    

Source: Eisai
Small and Easy to Take, Just One Tablet per Dose Eisai to Launch "Onji-No-Megumi" for Improving Forgetfulness in Middle Age and Beyond
Supporting the Power of Memory

TOKYO, Oct 11, 2017 - (JCN Newswire) - Eisai Co., Ltd. will launch Onji-no-Megumi (category-3 OTC drug), a medicine for improving forgetfulness in middle age and beyond, on October 10 (Tuesday) at pharmacies and drugstores countrywide.

Onji-no-Megumi (category-3 OTC drug)

Onji-no-Megumi is a category-3 OTC drug containing onji extract, which is indicated for "improving forgetfulness in middle age and beyond." Onji is an herbal medicine made from the dried roots of Polygala tenuifolia, mainly known for improving functions related to memory. Onji-no-Megumi is miniaturized herbal formulation which only requires one tablet per dose. Additionally, the tablet is coated to suppress the distinctive bitter flavor of herbal medicines, making it easy to take.

Based on a survey carried out by Eisai, over 40% of people aged 40 and over experience episodes of forgetfulness, such as "being unable to recall the name of a person or thing" or "mentioning the same thing over and over", and this makes them feel uneasy. However, at present, forgetfulness is considered to be natural consequence of aging and is thus difficult to treat. Onji-no-Megumi can be used to improve the memory functions of middle aged and older people who are concerned about forgetfulness.

Eisai is proactively engaged in spreading awareness of dementia and forgetfulness as well as in community building activities to support collaboration between stakeholders such as government, medical and care facilities.

Through the delivery of this product, Eisai seeks to further contribute to increasing the benefits provided to those who are concerned about forgetfulness, even in the area of self-medication.

http://www.acnnewswire.com/topimg/Low_EisaiOnjinoMegumi.jpg

About herbal medicine Onji

Onji is an herbal medicine made from the dried roots of Polygala tenuifolia. The name "onji" was recorded in the Compendium of Materia Medica, a classic Chinese text on medicinal plants, where it was named for its benefits of "increasing wisdom and strengthening will" and its powerful medicinal effect on the neuropsychiatric system. It was also found in the Shennong Ben Cao Jing, the oldest known Chinese medical text, and has historically been used in kamiuntanto (gallbladder warming decoctions), kamikihito (spleen restoration decoctions) and ninjinyoeito (ginseng nutrition decoctions).


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Feb 20, 2025 12:29 HKT/SGT
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
Feb 14, 2025 11:09 HKT/SGT
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
Feb 3, 2025 16:23 HKT/SGT
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
Jan 28, 2025 08:46 HKT/SGT
FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jan 22, 2025 16:18 HKT/SGT
Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company
Jan 15, 2025 09:03 HKT/SGT
FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jan 7, 2025 08:14 HKT/SGT
Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's Disease
Dec 23, 2024 16:22 HKT/SGT
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
Dec 11, 2024 13:45 HKT/SGT
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
Dec 5, 2024 10:22 HKT/SGT
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: